Chevy Chase Trust Holdings Inc. acquired a new position in The Cooper Cos. (NYSE:COO) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 40,815 shares of the medical device company’s stock, valued at approximately $7,317,000. Chevy Chase Trust Holdings Inc. owned 0.08% of The Cooper Cos. as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of COO. Adage Capital Partners GP L.L.C. bought a new stake in The Cooper Cos. during the first quarter worth $1,678,000. Legal & General Group Plc boosted its position in shares of The Cooper Cos. by 16.8% in the first quarter. Legal & General Group Plc now owns 32,069 shares of the medical device company’s stock valued at $4,938,000 after buying an additional 4,608 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in shares of The Cooper Cos. by 31.4% in the first quarter. Envestnet Asset Management Inc. now owns 14,177 shares of the medical device company’s stock valued at $2,183,000 after buying an additional 3,390 shares in the last quarter. Arizona State Retirement System boosted its position in shares of The Cooper Cos. by 2.5% in the first quarter. Arizona State Retirement System now owns 24,727 shares of the medical device company’s stock valued at $3,807,000 after buying an additional 600 shares in the last quarter. Finally, Royal Bank of Canada boosted its position in shares of The Cooper Cos. by 1.8% in the first quarter. Royal Bank of Canada now owns 155,661 shares of the medical device company’s stock valued at $23,968,000 after buying an additional 2,765 shares in the last quarter. 98.06% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for The Cooper Cos. (NYSE:COO)

The Cooper Cos. (NYSE:COO) traded up 1.22% during midday trading on Tuesday, reaching $170.38. The company’s stock had a trading volume of 284,818 shares. The firm has a 50-day moving average price of $176.26 and a 200 day moving average price of $175.93. The stock has a market capitalization of $8.30 billion, a price-to-earnings ratio of 33.36 and a beta of 0.62. The Cooper Cos. has a 52-week low of $119.28 and a 52-week high of $190.99.

The Cooper Cos. (NYSE:COO) last released its earnings results on Thursday, September 1st. The medical device company reported $2.30 EPS for the quarter, topping analysts’ consensus estimates of $2.29 by $0.01. The Cooper Cos. had a net margin of 13.14% and a return on equity of 14.89%. The firm earned $514.70 million during the quarter. During the same period in the prior year, the firm posted $1.97 EPS. The Cooper Cos.’s revenue was up 11.5% on a year-over-year basis. Equities research analysts predict that The Cooper Cos. will post $8.43 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Chevy Chase Trust Holdings Inc. Acquires New Stake in The Cooper Cos. (COO)” was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and republished in violation of international copyright & trademark legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2016/11/29/chevy-chase-trust-holdings-inc-acquires-new-stake-in-the-cooper-cos-coo.html.

COO has been the subject of several research reports. Jefferies Group lifted their price objective on The Cooper Cos. from $190.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, August 24th. Zacks Investment Research upgraded The Cooper Cos. from a “hold” rating to a “buy” rating and set a $202.00 price objective on the stock in a research note on Tuesday, November 8th. Robert W. Baird boosted their price objective on The Cooper Cos. from $185.00 to $196.00 and gave the stock an “outperform” rating in a research note on Thursday, August 18th. Stifel Nicolaus boosted their price objective on The Cooper Cos. from $195.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, August 31st. Finally, Wells Fargo & Co. restated a “hold” rating on shares of The Cooper Cos. in a research note on Sunday, September 11th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The Cooper Cos. presently has an average rating of “Buy” and a consensus price target of $187.80.

In other The Cooper Cos. news, EVP Albert G. White III sold 20,000 shares of The Cooper Cos. stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $185.72, for a total transaction of $3,714,400.00. Following the completion of the sale, the executive vice president now owns 41,639 shares of the company’s stock, valued at approximately $7,733,195.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William A. Kozy bought 270 shares of the stock in a transaction on Tuesday, September 6th. The shares were acquired at an average cost of $186.69 per share, with a total value of $50,406.30. Following the acquisition, the director now directly owns 770 shares in the company, valued at approximately $143,751.30. The disclosure for this purchase can be found here. Company insiders own 2.20% of the company’s stock.

About The Cooper Cos.

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

5 Day Chart for NYSE:COO

Receive News & Stock Ratings for The Cooper Cos. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Cooper Cos. and related stocks with our FREE daily email newsletter.